This post was originally published on this sitehttps://i-invdn-com.akamaized.net/news/LYNXMPEB2C0AG_M.jpg
Investing.com – Biomarin Pharma (NASDAQ:) reported on Wednesday fourth quarter that beat analysts’ forecasts and revenue that fell short of expectations.
Biomarin Pharma announced earnings per share of $0.08 on revenue of $454.4M. Analysts polled by Investing.com anticipated EPS of $-0.04 on revenue of $459.19M. That with comparison to EPS of $-0.03 on revenue of $353.2M in the same period a year before. Biomarin Pharma had reported EPS of $0.3 on revenue of $461.1M in the previous quarter. Analysts are expecting EPS of $0.01 and revenue of $472.76M in the upcoming quarter.
Biomarin Pharma shares are up 8.11% from the beginning of the year , still down 4.98% from its 52 week high of $96.20 set on March 4, 2019. They are outperforming the Nasdaq which is down 0.65% year to date.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma’s report follows an earnings beat by Merck&Co on February 5, who reported EPS of $1.16 on revenue of $11.87B, compared to forecasts EPS of $1.15 on revenue of $11.98B.
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.